During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 0.44 million, with the beta value of the company hitting 2.59. At the end of the trading day, the stock’s price was $0.48, reflecting an intraday loss of -2.04% or -$0.01. The 52-week high for the ADAP share is $2.05, that puts it down -327.08 from that peak though still a striking 4.17% gain since the share price plummeted to a 52-week low of $0.46. The company’s market capitalization is $122.82M, and the average trade volume was 1.61 million shares over the past three months.
Adaptimmune Therapeutics Plc ADR (ADAP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.89. ADAP has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Adaptimmune Therapeutics Plc ADR (ADAP) registered a -2.04% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.04% in intraday trading to $0.48, hitting a weekly high. The stock’s 5-day price performance is -11.11%, and it has moved by -18.21% in 30 days. Based on these gigs, the overall price performance for the year is -67.12%.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 84.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $4 respectively. As a result, ADAP is trading at a discount of -733.33% off the target high and -108.33% off the low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
In the rating firms’ projections, revenue will increase 204.78% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.01M as predicted by 8 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 6.3M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 231k and 5.68M respectively. In this case, analysts expect current quarter sales to grow by 3,798.81% and then jump by 10.95% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.30%. While earnings are projected to return 71.06% in 2025.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.65 million shares, is of BANK OF AMERICA CORP /DE/’s that is approximately 1.9239% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.53 million.
Also, the Mutual Funds coming in first place with the largest holdings of Adaptimmune Therapeutics Plc ADR (ADAP) shares are SPDR Portfolio Developed World ex-US ETF and SEI Institutional International Tr-International Equity . Data provided on Dec 31, 2024 indicates that SPDR Portfolio Developed World ex-US ETF owns about 251.08 shares. This amounts to just over 0.10 percent of the company’s overall shares, with a $0.12 million market value. The same data shows that the other fund manager holds slightly less at 246.74, or about 0.10% of the stock, which is worth about $0.12 million.
